2024 |
Ray M, Butel-Simoes LE, Lombard JM, Nordman IIC, Van der Westhuizen A, Collins NJ, et al., 'Women's cardiovascular health - the cardio-oncologic jigsaw.', Climacteric, 27 60-67 (2024) [C1]
|
|
Nova |
2024 |
Singleton AC, Redfern J, Diaz A, Koczwara B, Nicholls SJ, Negishi K, et al., 'Integrating CardioOncology Across the Research Pipeline, Policy, and Practice in Australia-An Australian Cardiovascular Alliance Perspective.', Heart Lung Circ, (2024) [C1]
|
|
|
2024 |
Balachandran L, Haw TJ, Leong AJW, Croft AJ, Chen D, Kelly C, et al., 'Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?', Heart Lung Circ, (2024) [C1]
|
|
|
2024 |
Collins NJ, Ngo DTM, Sverdlov AL, 'New cimlanod trial provides insights into mechanistic effects of vasodilators in heart failure', EUROPEAN JOURNAL OF HEART FAILURE, 26 152-154 (2024)
|
|
|
2024 |
Gomez HM, Haw TJ, Ilic D, Robinson P, Donovan C, Croft AJ, et al., 'Landscape fire smoke airway exposure impairs respiratory and cardiac function and worsens experimental asthma', Journal of Allergy and Clinical Immunology, (2024)
|
|
|
2023 |
Williams TD, Ngo DTM, Sverdlov AL, 'Examining real world quality of care for Australia's First Peoples presenting with chest pain', LANCET REGIONAL HEALTH-WESTERN PACIFIC, 38 (2023)
|
|
|
2023 |
Chen D, Untaru R, Stavropoulou G, Assadi-Khansari B, Kelly C, Croft AJ, et al., 'Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)', Journal of Clinical Medicine, 12 2790-2790 [C1]
|
|
Nova |
2023 |
Williams TD, Kaur A, Warner T, Aslam M, Clark V, Walker R, et al., 'Cardiovascular outcomes of cancer patients in rural Australia', Frontiers in Cardiovascular Medicine, 10 (2023) [C1]
Background: Cancer and heart disease are the two most common health conditions in the world, associated with high morbidity and mortality, with even worse outcomes in regional are... [more]
Background: Cancer and heart disease are the two most common health conditions in the world, associated with high morbidity and mortality, with even worse outcomes in regional areas. Cardiovascular disease is the leading cause of death in cancer survivors. We aimed to evaluate the cardiovascular outcomes of patients receiving cancer treatment (CT) in a regional hospital. Methods: This was an observational retrospective cohort study in a single rural hospital over a ten-year period (17th February 2010 to 19th March 2019). Outcomes of all patients receiving CT during this period were compared to those who were admitted to the hospital without a cancer diagnosis. Results: 268 patients received CT during the study period. High rates of cardiovascular risk factors: hypertension (52.2%), smoking (54.9%), and dyslipidaemia (38.4%) were observed in the CT group. Patients who had CT were more likely to be readmitted with ACS (5.9% vs. 2.8% p = 0.005) and AF (8.2% vs. 4.5% p = 0.006) when compared to the general admission cohort. There was a statistically significant difference observed for all cause cardiac readmission, with a higher rate observed in the CT group (17.1% vs. 13.2% p = 0.042). Patients undergoing CT had a higher rate of mortality (49.5% vs. 10.2%, p = 0.001) and shorter time (days) from first admission to death (401.06 vs. 994.91, p = 0.001) when compared to the general admission cohort, acknowledging this reduction in survival may be driven at least in part by the cancer itself. Conclusion: There is an increased incidence of adverse cardiovascular outcomes, including higher readmission rate, higher mortality rate and shorter survival in people undergoing cancer treatment in rural environments. Rural cancer patients demonstrated a high burden of cardiovascular risk factors.
|
|
Nova |
2023 |
Leitch V, Ngo D, Sverdlov A, 'Hypertension after anti-cancer therapy', HEART LUNG AND CIRCULATION, 32 1407-1407 (2023)
|
|
|
2023 |
Croft AJ, Kelly C, Chen D, Haw TJ, Sverdlov AL, Ngo DTM, 'Overexpression of Mitochondrial Catalase within Adipose Tissue Does Not Confer Systemic Metabolic Protection against Diet-Induced Obesity.', Antioxidants (Basel), 12 (2023) [C1]
|
|
Nova |
2023 |
Kelly CJ, Chu M, Untaru R, Assadi-Khansari B, Chen D, Croft AJ, et al., 'Association of Circulating Plasma Secreted Frizzled-Related Protein 5 (Sfrp5) Levels with Cardiac Function', Journal of Cardiovascular Development and Disease, 10 274-274 [C1]
|
|
Nova |
2023 |
Butel-Simoes LE, Haw TJ, Williams T, Sritharan S, Gadre P, Herrmann SM, et al., 'Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.', Hypertension, 80 685-710 (2023) [C1]
|
|
Nova |
2023 |
McGee M, Shephard L, Sugito S, Baker D, Brienesse S, Al-Omary M, et al., 'Mind The Gap, Aboriginal and Torres Strait Islander Cardiovascular Health: A Narrative Review', Heart Lung and Circulation, 32 136-142 (2023) [C1]
Australia's First Nations Peoples, Aboriginal and Torres Strait Islanders, have reduced life expectancy compared to the wider community. Cardiovascular diseases, mainly drive... [more]
Australia's First Nations Peoples, Aboriginal and Torres Strait Islanders, have reduced life expectancy compared to the wider community. Cardiovascular diseases, mainly driven by ischaemic heart disease, are the leading contributors to this disparity. Despite over a third of First Nations Peoples living in New South Wales, the bulk of the peer-reviewed literature is from Central Australia and Far North Queensland. Regardless of the site of publication, First Nations Peoples are significantly younger at disease onset and have higher rates of comorbidities, in turn driving adverse health events. On top of this, very few First Nations Peoples specific cardiovascular interventions or programs have been shown to improve outcomes. The traditional biomedical model of care is less efficacious and non-traditional models of communication such as clinical yarning may benefit both clinicians and patients. The key purpose of this review is to highlight the deficiencies of our knowledge of cardiovascular burden of disease for First Nations Peoples; and to serve as a catalyst for more dedicated research. We need to have relationships with communities and concentrate on community improvement and partnerships. By involving First Nations Peoples researchers in collaboration with local communities in all levels of health care design and intervention will improve outcomes.
|
|
Nova |
2023 |
Murtha LA, Hardy SA, Mabotuwana NS, Bigland MJ, Bailey T, Raguram K, et al., 'Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction', Scientific Reports, 13 (2023) [C1]
Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural int... [more]
Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural integrity, however its role in the heart is unknown. We have demonstrated, using single cell RNA-seq, that fibulin-3 was highly expressed in quiescent murine cardiac fibroblasts, with expression highest prior to injury and late post-infarct (from ~ day-28 to week-8). In humans, fibulin-3 was upregulated in left ventricular tissue and plasma of heart failure patients. Fibulin-3 knockout (Efemp1 -/-) and wildtype mice were subjected to experimental myocardial infarction. Fibulin-3 deletion resulted in significantly higher rate of cardiac rupture days 3¿6 post-infarct, indicating a weak and poorly formed scar, with severe ventricular remodelling in surviving mice at day-28 post-infarct. Fibulin-3 knockout mice demonstrated less collagen deposition at day-3 post-infarct, with abnormal collagen fibre-alignment. RNA-seq on day-3 infarct tissue revealed upregulation of ECM degradation and inflammatory genes, but downregulation of ECM assembly/structure/organisation genes in fibulin-3 knockout mice. GSEA pathway analysis showed enrichment of inflammatory pathways and a depletion of ECM organisation pathways. Fibulin-3 originates from cardiac fibroblasts, is upregulated in human heart failure, and is necessary for correct ECM organisation/structural integrity of fibrotic tissue to prevent cardiac rupture post-infarct.
|
|
Nova |
2022 |
Nolan M, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon A, et al., 'First ESC Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty', Heart Lung and Circulation, 31 1563-1567 (2022)
|
|
|
2022 |
Deng Y, Ngo DTM, Holien JK, Lees JG, Lim SY, 'Mitochondrial Dynamin-Related Protein Drp1: a New Player in Cardio-oncology', CURRENT ONCOLOGY REPORTS, 24 1751-1763 (2022) [C1]
|
|
Nova |
2022 |
White J, Byles J, Williams T, Untaru R, Ngo DTM, Sverdlov AL, 'Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences', CARDIO-ONCOLOGY, 8 (2022) [C1]
|
|
Nova |
2022 |
Al-Omary MS, Majeed T, Al-Khalil H, Sugito S, Clapham M, Ngo DTM, et al., 'Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting', Open Heart, 9 (2022) [C1]
Aims This study aims to (1) define the characteristics of patients with a first admission for heart failure (HF), stratified by type (reduced (HFrEF) vs preserved (HFpEF) ejection... [more]
Aims This study aims to (1) define the characteristics of patients with a first admission for heart failure (HF), stratified by type (reduced (HFrEF) vs preserved (HFpEF) ejection fraction) in a regional Australian setting; (2) compare the outcomes in terms of mortality and rehospitalisation and (3) assess adherence to the treatment guidelines. Methods We identified all index hospitalisations with HF to John Hunter Hospital and Tamworth Rural Referral Hospital in the Hunter New England Local Health District over a 12 months. We used the recent Australian HF guidelines to classify HFrEF and HFpEF and assess adherence to guideline-directed therapy. The primary outcome of the study was to compare short-term (1 year) and long-term all-cause mortality and the composite of all-cause hospitalisation or all-cause mortality of patients with HFrEF and HFpEF. Results There were 664 patients who had an index HF admission to John Hunter and Tamworth hospitals in 2014. The median age was 80 years, 47% were female and 22 (3%) were Aboriginal. In terms of HF type, 29% had HFrEF, 37% had HFpEF, while the remainder (34%) did not have an echocardiogram within 1 year of admission and could not be classified. The median follow-up was 3.3 years. HFrEF patients were predominantly male (64%) and in 48% the aetiology was ischaemic heart disease. The 1-year all-cause mortality was 23% in HFpEF subgroup and 29% in HFrEF subgroup (p=0.15). Five-year mortality was 61% in HFpEF and HFrEF patients. Of the HFrEF patients, only 61% were on renin-angiotensin-aldosterone blockers, 74% were on ß-blockers and 39% were on aldosterone antagonist. Conclusion HF patients are elderly and about evenly split between HFrEF and HFpEF. In this regional cohort, both HF types are associated with similar 1-year and 5-year mortality following incident HF hospitalisation. Echocardiography and guideline-directed therapies were underused.
|
|
Nova |
2022 |
Nolan M, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon A, et al., 'First ESC Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty', Heart Lung and Circulation, 31 1563-1567 (2022)
|
|
|
2021 |
Cehic DA, Sverdlov AL, Koczwara B, Emery J, Ngo DTM, Thornton-Benko E, 'The Importance of Primary Care in Cardio-Oncology', CURRENT TREATMENT OPTIONS IN ONCOLOGY, 22 (2021) [C1]
|
|
Nova |
2021 |
Chen D, Kelly C, Haw TJ, Lombard JM, Nordman IIC, Croft AJ, et al., 'Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers', Current Heart Failure Reports, 18 362-377 (2021) [C1]
Purpose of Review: Breast cancer survival rate has greatly improved in the last two decades due to the emergence of next-generation anti-cancer agents. However, cardiotoxicity rem... [more]
Purpose of Review: Breast cancer survival rate has greatly improved in the last two decades due to the emergence of next-generation anti-cancer agents. However, cardiotoxicity remains a significant adverse effect arising from traditional and emerging chemotherapies as well as targeted therapies for breast cancer patients. In this review, we will discuss cardiotoxicities of both traditional and emerging therapies for breast cancer. We will discuss current practices to detect cardiotoxicity of these therapies with the focus on new and emerging biomarkers. We will then focus on ¿omics approaches, especially the use of epigenetics to discover novel biomarkers and therapeutics to mitigate cardiotoxicity. Recent Findings: Significant cardiotoxicities of conventional chemotherapies remain and new and unpredictable new forms of cardiac and/or vascular toxicity emerge with the surge in novel and targeted therapies. Yet, there is no clear guidance on detection of cardiotoxicity, except for significant left ventricular systolic dysfunction, and even then, there is no uniform definition of what constitutes cardiotoxicity. The gold standard for detection of cardiotoxicity involves a serial echocardiography in conjunction with blood-based biomarkers to detect early subclinical cardiac dysfunction. However, the ability of these tests to detect early disease remains limited and not all forms of toxicity are detectable with these modalities. Summary: There is an unprecedented need to discover novel biomarkers that are sensitive and specific for early detection of subclinical cardiotoxicity. In that space, novel echocardiographic techniques, such as strain, are becoming more common-place and new biomarkers, discovered by epigenetic approaches, seem to become promising alternatives or adjuncts to conventional non-specific cardiac biomarkers.
|
|
Nova |
2021 |
Ell P, Martin JM, Cehic DA, Ngo DTM, Sverdlov AL, 'Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation', Current Treatment Options in Oncology, 22 (2021) [C1]
Radiation therapy is a key component of modern-day cancer therapy and can reduce the rates of recurrence and death from cancer. However, it can increase risk of cardiovascular (CV... [more]
Radiation therapy is a key component of modern-day cancer therapy and can reduce the rates of recurrence and death from cancer. However, it can increase risk of cardiovascular (CV) events, and our understanding of the timeline associated with that risk is shorter than previously thought. Risk mitigation strategies, such as different positioning techniques, and breath hold acquisitions as well as baseline cardiovascular risk stratification that can be undertaken at the time of radiotherapy planning should be implemented, particularly for patients receiving chest radiation therapy. Primary and secondary prevention of cardiovascular disease (CVD), as appropriate, should be used before, during, and after radiation treatment in order to minimize the risks. Opportunistic screening for subclinical coronary disease provides an attractive possibility for primary/secondary CVD prevention and thus mitigation of long-term CV risk. More data on long-term clinical usefulness of this strategy and development of appropriate management pathways would further strengthen the evidence for the implementation of such screening. Clear guidelines in initial cardiovascular screening and cardiac aftercare following radiotherapy need to be formulated in order to integrate these measures into everyday clinical practice and policy and subsequently improve post-treatment morbidity and mortality for these patients.
|
|
Nova |
2021 |
Butel-Simoes LE, Ngo DTM, Sverdlov AL, 'Digital Technologies to Help Delivery of Cardio-Oncology Care', HEART LUNG AND CIRCULATION, 30 1271-1273 (2021)
|
|
|
2021 |
McGee M, Sugito S, Al-Omary MS, Hartnett D, Senanayake T, Hales K, et al., 'Heart failure outcomes in Aboriginal and Torres Strait Islander peoples in the Hunter New England region of New South Wales', INTERNATIONAL JOURNAL OF CARDIOLOGY, 334 65-71 (2021) [C1]
|
|
Nova |
2020 |
Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, et al., 'Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab', JOURNAL OF CLINICAL MEDICINE, 9 (2020) [C1]
|
|
Nova |
2020 |
Untaru R, Chen D, Kelly C, May A, Collins NJ, Leitch J, et al., 'Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer', JACC: CARDIOONCOLOGY, 2 312-315 (2020) [C1]
|
|
Nova |
2020 |
Diaz A, Sverdlov AL, Kelly B, Ngo DTM, Bates N, Garvey G, 'Nexus of cancer and cardiovascular disease for Australia's first peoples', Journal of Global Oncology, 2020 115-119 (2020) [C1]
|
|
Nova |
2020 |
Kirana C, Smith E, Ngo DT, Trochsler MI, Hewett PJ, Stubbs RS, et al., 'High preoperative levels of circulating SFRP5 predict better prognosis in colorectal cancer patients.', Future oncology (London, England), 16 2499-2509 (2020) [C1]
|
|
Nova |
2020 |
Liu S, Ngo D, Chirkov Y, Stansborough J, Chong C-R, Horowitz JD, 'Prolonged suppression of the anti-oxidant/anti-inflammatory effects of BNP post-Takotsubo syndrome.', ESC heart failure, 7 2250-2257 (2020) [C1]
|
|
Nova |
2019 |
Croft AJ, Ngo DTM, Sverdlov AL, 'Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again', HEART LUNG AND CIRCULATION, 28 1454-1456 (2019)
|
|
Nova |
2019 |
Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ, 'Ibrutinib-related atrial fibrillation: A single center Australian experience', Asia-Pacific Journal of Clinical Oncology, 15 e187-e190 (2019) [C1]
Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. Th... [more]
Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. The aim of the current analysis was to evaluate the incidence of AF in a single-center cohort of patients. Methods: This analysis was conducted at Hunter New England Local Health District, Australia between April 1, 2015 and June 30, 2017. We included all consecutive patients commenced on ibrutinib for hematological malignancies. Patients with a history of paroxysmal AF were excluded. The primary end point was incidence of AF. Time to diagnosis and management were secondary outcomes of interest. Results: A total of 24 patients (age 73¿±¿9 years, males n¿=¿16 [67%]) were commenced on ibrutinib treatment during the study period with chronic lymphocytic leukemia (n¿=¿21, 88%) as the main indication. During a median follow-up of 12 months, four (17%) patients were diagnosed with AF with increasing age, duration of ibrutinib treatment as associations. The median time to AF diagnosis was 9 (interquartile range [IQR]: 7-18) months. All patients were managed with a rate control strategy with beta blockers as the preferred agents. Three (75%) patients were commenced on anticoagulation for stroke prevention. During a follow-up of 18 (IQR: 17-23) months following AF onset, one patient required hospitalization for AF. There were no bleeding complications reported. Conclusions: In conclusion, this series noted a higher incidence of AF than previously reported. Oncologists and cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib.
|
|
Nova |
2019 |
Figtree GA, Ngo DTM, Bubb KJ, 'Testosterone to estradiol ratio and plaque inflammation: Mechanistic insights and biomarker potential?', Cardiovascular Research, 115 255-257 (2019)
|
|
Nova |
2018 |
Surikow SY, Nguyen TH, Stafford I, Chapman M, Chacko S, Singh K, et al., 'Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome', JACC-BASIC TO TRANSLATIONAL SCIENCE, 3 213-226 (2018) [C1]
|
|
|
2017 |
Karki S, Ngo DTM, Farb MG, Park SY, Saggese SM, Hamburg NM, et al., 'WNT5A regulates adipose tissue angiogenesis via antiangiogenic VEGF-A(165)b in obese humans', AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 313 H200-H206 (2017) [C1]
|
|
|
2017 |
Amarasekera AT, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, et al., 'Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults', PLOS ONE, 12 (2017) [C1]
|
|
|
2017 |
Sverdlov AL, Ngo DTM, 'Response to the letter to editor: Galectin-3 and atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 229 2-2 (2017)
|
|
|
2017 |
Canavese M, Ngo DTM, Maddern GJ, Hardingham JE, Price TJ, Hauben E, 'Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer', INTERNATIONAL JOURNAL OF CANCER, 140 2183-2191 (2017) [C1]
|
|
|
2016 |
Sverdlov AL, Figtree GA, Horowitz JD, Ngo DTM, 'Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome', MEDIATORS OF INFLAMMATION, 2016 (2016)
|
|
|
2016 |
Procter NEK, Ball J, Ngo DTM, Isenberg JS, Hylek EM, Chirkov YY, et al., 'Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation', JOURNAL OF GERIATRIC CARDIOLOGY, 13 202-208 (2016) [C1]
|
|
|
2016 |
Procter NEK, Ball J, Ngo DTM, Chirkov YY, Isenberg JS, Hylek EM, et al., 'Platelet hyperaggregability in patients with atrial fibrillation Evidence of a background proinflammatory milieu', HERZ, 41 57-62 (2016) [C1]
|
|
|
2015 |
Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)
|
|
|
2015 |
Fuster JJ, Zuriaga MA, Doan T-MN, Farb MG, Aprahamian T, Yamaguchi TP, et al., 'Noncanonical Wnt Signaling Promotes Obesity-Induced Adipose Tissue Inflammation and Metabolic Dysfunction Independent of Adipose Tissue Expansion', DIABETES, 64 1235-1248 (2015)
|
|
|
2015 |
Procter NEK, Ball J, Liu S, Hurst N, Nooney VB, Goh V, et al., 'Impaired platelet nitric oxide response in patients with new onset atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 179 160-165 (2015)
|
|
|
2015 |
Karki S, Farb MG, Ngo DTM, Myers S, Puri V, Hamburg NM, et al., 'Forkhead Box O-1 Modulation Improves Endothelial Insulin Resistance in Human Obesity', ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 35 1498-1506 (2015)
|
|
|
2015 |
Liu S, Ngo DTM, Chong C-R, Amarasekera AT, Procter NEK, Licari G, et al., 'Suppression of neutrophil superoxide generation by BNP is attenuated in acute heart failure: a case for 'BNP resistance'', EUROPEAN JOURNAL OF HEART FAILURE, 17 475-483 (2015)
|
|
|
2015 |
Procter NEK, Ball J, Heresztyn T, Nooney VB, Liu S, Chong C-R, et al., 'Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 5 101-109 (2015)
|
|
|
2015 |
Chong C-R, Liu S, Licari G, Heresztyn T, Chirkov YY, Ngo DT, Horowitz JD, 'Reversal of hyperglycemia: effects on nitric oxide signaling.', Am J Med, 128 427-430 (2015)
|
|
|
2015 |
Ngo DT, Gokce N, 'Epicardial adipose tissue: a benign consequence of obesity?', Circ Cardiovasc Imaging, 8 (2015)
|
|
|
2014 |
Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)
|
|
|
2014 |
Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)
|
|
|
2014 |
Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)
|
|
|
2014 |
Karki S, Ngo DTM, Bigornia SJ, Farb MG, Gokce N, 'Insulin resistance: a key therapeutic target for cardiovascular risk reduction in obese patients?', EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 9 93-95 (2014)
|
|
|
2014 |
Ngo DTM, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, et al., 'Antiangiogenic Actions of Vascular Endothelial Growth Factor-A(165)b, an Inhibitory Isoform of Vascular Endothelial Growth Factor-A, in Human Obesity', CIRCULATION, 130 1072-1080 (2014)
|
|
|
2014 |
Kikuchi R, Nakamura K, MacLauchlan S, Doan T-MN, Shimizu I, Fuster JJ, et al., 'An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease', NATURE MEDICINE, 20 1464-1471 (2014)
|
|
|
2014 |
Liu S, Ngo DTM, Stewart S, Horowitz JD, Chirkov YY, 'B-Type natriuretic peptide suppression of neutrophil superoxide generation: mechanistic studies in normal subjects', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 41 739-743 (2014)
|
|
|
2014 |
Farb MG, Tiwari S, Karki S, Ngo DTM, Carmine B, Hess DT, et al., 'Cyclooxygenase Inhibition Improves Endothelial Vasomotor Dysfunction of Visceral Adipose Arterioles in Human Obesity', OBESITY, 22 349-355 (2014)
|
|
|
2013 |
Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)
|
|
|
2012 |
Ngo DT, Sverdlov AL, Horowitz JD, 'Prevention of aortic valve stenosis: A realistic therapeutic target?', PHARMACOLOGY & THERAPEUTICS, 135 78-93 (2012)
|
|
|
2012 |
Sverdlov AL, Ngo DT, Horowitz JD, 'Redefining the natural history of calcific aortic stenosis: lessons from Laennec', JOURNAL OF INTERNAL MEDICINE, 271 569-572 (2012)
|
|
|
2012 |
Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD, 'Determinants of aortic sclerosis progression: Implications regarding impairment of nitric oxide signalling and potential therapeutics', European Heart Journal, 33 2419-2425 (2012) [C1]
|
|
|
2012 |
Sverdlov AL, Ngo DTM, Horowitz JD, 'Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2 43-49 (2012)
|
|
|
2012 |
Zhang J, Youn JY, Kim AY, Ramirez RJ, Gao L, Ngo D, et al., 'NOX4-dependent hydrogen peroxide overproduction in human atrial fibrillation and HL-1 atrial cells: Relationship to hypertension', Frontiers in Physiology, 3 JUN (2012)
Background/Objectives: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia with patients dying frequently of stroke. In view of the unclear etiologies of AF and... [more]
Background/Objectives: Atrial fibrillation (AF) is the most common type of cardiac arrhythmia with patients dying frequently of stroke. In view of the unclear etiologies of AF and a potential role of oxidative stress, the present study examined cardiac reactive oxygen species production and NADPH oxidase (NOX) expression in AF patients. Methods and Results: Patients with AF were older than those without (58.8± 11.7 vs. 47.8±19.2, p = 0.047). Whereas total OZ.ast;~ production (determined by electron spin resonance) was similar in patients with and without AF, H2O2 production was more than doubled in AF patients (149.8 ±26.28 vs. 66.9±7.14pmol/mg/min, p= 0.0055), which correlated well with a doubling in NOX isoform 4 (NOX4) expression. AF patients with co-existing hypertension had three-fold higher H2O2 production compared to those without (239.0± 125.1 vs. 83.6± 51.3pmol/mg/min, p = 0.003). Treatment of HL-1 atrial cells with angiotensin II, a known modulator of atrial structural remodeling, resulted in upregulation of NOX4 and H2O2 production, further implicating a potential role of NOX4 in atrial remodeling. Conclusion: Our data represent the first implication that NOX4-derived H 2O 2 may play an important role in the etiologies of AF. © 2012 Zhang, Youn, Kim, Ramirez, Gao, Ngo, Chen, Scovotti, Mahajan and Cai.
|
|
|
2011 |
Nightingale AK, Sverdlov AL, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD, 'Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects', INTERNATIONAL JOURNAL OF CARDIOLOGY, 150 33-38 (2011)
|
|
|
2011 |
Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 326-330 (2011)
|
|
|
2010 |
Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD, 'Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?', AMERICAN JOURNAL OF MEDICINE, 123 335-341 (2010)
|
|
|
2009 |
Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD, 'Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine', PHARMACOLOGICAL RESEARCH, 60 503-507 (2009)
|
|
|
2009 |
Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD, 'Determinants of Occurrence of Aortic Sclerosis in an Aging Population', JACC-CARDIOVASCULAR IMAGING, 2 919-927 (2009)
|
|
|
2008 |
Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, et al., 'Vitamin D
|
|
|
2007 |
Ngo DTM, Heresztyn T, Mishra K, Marwick TH, Horowitz JD, 'Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA)', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 16 197-201 (2007)
|
|
|
2004 |
Ngo DTM, Wuttke RD, Turner S, Marwick TH, Horowitz JD, 'Quantitative assessment of aortic sclerosis using ultrasonic backscatter', JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 17 1123-1130 (2004)
|
|
|
1973 |
McLaren J, Ngo DT, Olivera BM, 'Pyridine nucleotide metabolism in Escherichia coli. 3. Biosynthesis from alternative precursors in vivo.', The Journal of biological chemistry, 248 5144-5149 (1973)
|
|
|